UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: September 30, 1999
Check here if Amendment: |_|; Amendment Number: ____
This Amendment (Check only one): |_| is a restatement.
|_| adds new holdings
entries.
Institutional Investmtne Manager Filing this Report:
Name: OrbiMed Advisers Inc.
Address: 767 Third Avenue, 6th Floor
New York, NY 10010
Form 13F File Number: 28-6776
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables, are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Samuel D. Isaly
Title: President
Phone: (212) 739-6400
Signature, Place, and Date of Signing:
Samuel D. Isaly New York, NY November 12, 1999
[Signature] [City, State] [Date]
Report Type (Check one only):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
<PAGE>
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 1
Form 13F Information Table Entry Total: 46
Form 13F Information Table Value Total: $ 370,737
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file nember(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings
and list entries.]
No. Form 13F File Number Name
2 28-6774 OrbiMed Advisors LLC
<PAGE>
FORM 13F INFORMATION TABLE
PAGE 1
<TABLE>
<CAPTION>
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
- ------------------ ------------ -------- -------- -------- ---------- -------- --------------------
TITLE OF VALUE SHRS OR INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT DISCRETION MANAGERS SOLE
- ------------------ ------------ -------- -------- ------- ---------- -------- ----
SOLE
----
<S> <C> <C> <C> <C> <C> <C> <C>
Abgenix, Inc COM 00339B107 10,851,920 276,923 X 1 276,923
Abgenix, Inc COM 00339B107 11,349,288 289,615 X 2 289,615
Alexion Pharmaceuticals, COM 015351109 3,982,500 270,000 X 1 270,000
Inc.
Alexion Pharmaceuticals, COM 015351109 6,497,375 440,500 X 2 440,500
Inc.
Aquila COM 03839f107 947,937 523,000 X 2 523,000
Biopharmaceuticals
Aradigm Corp COM 38505103 1,391,562 152,500 X 2 152,500
Aviron COM 053762100 6,062,500 250,000 X 1 250,000
Aviron COM 053762100 8,475,375 349,500 X 2 349,500
BioChem Pharma Inc. COM 09058T108 3,542,750 148,000 X 2 148,000
Bio-Technology General COM 090578105 3,837,500 400,000 X 1 400,000
Bio-Technology General COM 090578105 2,878,125 300,000 X 2 300,000
Chiron Corp. COM 170040109 3,433,250 124,000 X 2 124,000
Chromavision Medical COM 17111P104 25,000 2,000 X 2 2,000
Systems
Coulter Pharmaceutical COM 222116105 1,017,437 73,000 X 2 73,000
Inc.
CV Therapeutics COM 126667104 4,482,562 306,500 X 2 306,500
Discovery Laboratories COM 254668106 2,272,726 1,652,892 X 2 1,652,892
Inc.
Eli Lilly & Company COM 532457108 9,628,125 150,000 X 1 150,000
Eli Lilly & Company COM 532457108 16,046,875 250,000 X 2 250,000
Enzon Inc. COM 293904108 4,117,500 135,000 X 2 135,000
Forest Laboratories - CL A COM 345838106 3,622,750 86,000 X 2 86,000
Genzyme Corp. General COM 372917104 6,759,375 150,000 X 1 150,000
Division
Genzyme Corp. General COM 372917104 14,960,750 332,000 X 2 332,000
Division
Gilead Sciences Inc. COM 375558103 6,418,750 100,000 X 1 100,000
<PAGE>
Gilead Sciences Inc. COM 375558103 12,131,437 189,000 X 2 189,000
Hyseq Inc. COM 449163302 1,107,975 224,400 X 2 224,400
Incyte Pharmaceuticals COM 45337C102 2,543,750 110,000 X 1 110,000
Inc.
Incyte Pharmaceuticals COM 45337C102 5,550,000 240,000 X 2 240,000
Inc.
Merck, Inc. COM 589331107 7,129,375 110,000 X 1 110,000
Merck, Inc. COM 589331107 881,450 136,000 X 2 136,000
Monsanto COM 611662107 89,221,875 250,000 X 1 250,000
Monsanto COM 611662107 15,274,250 428,000 X 2 428,000
Neotherapeutics Inc. COM 640656104 910,000 80,000 X 2 80,000
Pharmacia and Upjohn COM 716941109 5,955,000 120,000 X 1 120,000
Inc.
Pharmacia and Upjohn COM 716941109 16,946,937 341,500 X 2 341,500
Inc.
Pharmacopeia Inc. COM 71713B104 3,806,250 350,000 X 1 350,000
Pharmacopeia Inc. COM 71713B104 4,594,687 422,500 X 2 422,500
Premier Research COM 740568100 1,351,250 235,000 X 1 235,000
Worldwide
SangStat Medical Corp. COM 801003104 5,557,500 260,000 X 1 260,000
SangStat Medical Corp. COM 801003104 9,105,750 426,000 X 2 426,000
Titan Pharmaceutical COM 888314101 3,506,250 374,000 X 2 374,000
Triangle Pharmaceutical COM 89589H104 3,850,000 200,000 X 1 200,000
Triangle Pharmaceutical COM 89589H104 3,368,750 175,000 X 2 175,000
Vertex Pharmaceuticals COM 92532F100 6,989,062 225,000 X 1 225,000
Inc.
Vertex Pharmaceuticals COM 92532F100 11,803,750 380,000 X 2 380,000
Inc.
Warner-Lambert Co. COM 934488107 9,376,730 141,269 X 1 141,269
Warner-Lambert Co. COM 934488107 17,172,540 258,720 X 2 258,720
- ----------------------------------------------------------- -----------------------------------------------------
Total 370,736,500 12,437,819 12,437,819
- ----------------------------------------------------------- -----------------------------------------------------
</TABLE>
